



EVERY *BREATH* MATTERS.

2 INDICATIONS, 1 VACCINE – help protect those at greatest risk from RSV.¹

ABRYSVO IS INDICATED FOR THE ACTIVE IMMUNISATION OF:

Individuals 60 years of age and above for prevention of LRTD caused by RSV.¹

Pregnant women between 24–36 weeks of gestation for the prevention of LRTD caused by RSV in infants from birth through to 6 months of age.¹

ABRYSVO should be used in accordance with official recommendations.¹
LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus.

Scan the QR codes to learn more about RSV and how you can help protect two vulnerable populations* from RSV-associated LRTD.^{1,2}

*Infants, via maternal immunisation, and adults aged 60 years and older.¹



ABRYSVO PfizerPro
Website



Instructions for Use
Poster



Instructions for Use
Video



Take a Breath
Podcast



HCP Leaflet



Australian Immunisation
Handbook

HCP, healthcare professional; LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus.



This vaccine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.



PBS Information: ABRYSVO is not listed on the PBS or the NIP.

Before prescribing, please review the approved Product Information by scanning the QR code.

The most common adverse events reported by adults who received ABRYSVO in clinical trials were: headache, myalgia and vaccination site pain (very common); and vaccination site redness and swelling (common).¹ Please refer to the PI for further information.

References: 1. ABRYSVO Approved Product Information. 2. Australian Government Department of Health and Aged Care. Therapeutic Goods Administration (TGA). ABRYSVO (Pfizer Australia Pty Ltd). Public Summary, 20/03/2024.

Abrysvo® is a registered trademark. © 2024 Pfizer Australia Pty Ltd. Sydney, Australia. All rights reserved.
Pfizer Medical Information: 1800 675 229. PP-A1G-AUS-0069. ABR-002669-00. May 2024.

